Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme

Journal of Controlled Release

Volumn 129, Issue 1, 2008, Pages 41-48

  Cheng, Mao Bo ^a,b   Wang, Jian Cheng ^a   Li, Yu Hua ^a   Liu, Xiao Yan ^a   Zhang, Xuan ^a   Chen, Da Wei ^b   Zhou, Shu Feng ^c   Zhang, Qiang ^a,d  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^d PEKING UNIVERSITY   (China)

Author keywords

Bioactive macromolecules; Earthworm fibrinolytic enzyme; Microemulsion; Oral

Indexed keywords

BIOACTIVITY; MACROMOLECULES; MICROEMULSIONS;

BIOACTIVE MACROMOLECULES; EARTHWORM FIBRINOLYTIC ENZYME;

ENZYME ACTIVITY;

CAPRIC TRIGLYCERIDE; EARTHWORM FIBRINOLYTIC ENZYME; EMULSIFYING AGENT; EXCIPIENT; FLUORESCEIN ISOTHIOCYANATE; LABRAFAC CC; LABRASOL; OCTANOIC ACID; OCTANOIN; PLASMIN; PLUROL OLEIQUE CC 497; POLYETHYLENE GLYCOL 8 GLYCERYL CAPRATE; POLYGLYCEROL 6 DIOLEATE; SODIUM CHLORIDE; SURFACTANT; TRIACYLGLYCEROL; WATER OIL CREAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE CONDUCTANCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; INTESTINE MUCOSA PERMEABILITY; MACROMOLECULE; MALE; MEMBRANE PERMEABILITY; MICROEMULSION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; VISCOSITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; ELECTRIC CONDUCTIVITY; EMULSIONS; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTUBATION, GASTROINTESTINAL; MALE; OILS; OLEIC ACIDS; OLIGOCHAETA; ORGANIC CHEMICALS; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SERINE ENDOPEPTIDASES; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL; VISCOSITY; WATER;

EID: 44649083065     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.03.018     Document Type: Article

References (47)

1. Frokjaer S., and Otzen D.E. Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4 4 (2005) 298-306
2. Mustata G., and Dinh S.M. Approaches to oral drug delivery for challenging molecules. Crit. Rev. Ther. Drug Carr. Syst. 23 2 (2006) 111-135
3. Mahato R.I., Narang A.S., Thoma L., and Miller D.D. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carr. Syst. 20 2-3 (2003) 153-214
4. Hamman J.H., Enslin G.M., and Kotze A.F. Oral delivery of peptide drugs: barriers and developments. BioDrugs 19 3 (2005) 165-177
5. Shah R.B., Ahsan F., and Khan M.A. Oral delivery of proteins: progress and prognostication. Crit. Rev. Ther. Drug. Carrier. Syst. 19 2 (2002) 135-169
6. Van Der Lubben I.M., Konings F.A., Borchard G., Verhoef J.C., and Junginger H.E. In vivo uptake of chitosan microparticles by murine Peyer's patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry. J. Drug Target. 9 1 (2001) 39-47
7. Russell-Jones G.J. Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium. J. Drug Target. 12 2 (2004) 113-123
8. Kipnes M., Dandona P., Tripathy D., Still J.G., and Kosutic G. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 26 2 (2003) 421-426
9. Spernath A., and Aserin A. Microemulsions as carriers for drugs and nutraceuticals. Adv. Colloid Interface Sci. 128-130 (2006) 47-64
10. Jadhav K.R., Shaikh I.M., Ambade K.W., and Kadam V.J. Applications of microemulsion based drug delivery system. Curr. Drug. Deliv. 3 3 (2006) 267-273
11. Ritschel W.A. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Clin. Transplant. 10 4 (1996) 364-373
12. Constantinides P.P., Scalart J.P., Lancaster C., Marcello J., Marks G., Ellens H., and Smith P.L. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm. Res. 11 10 (1994) 1385-1390
13. Prasad Y.V., Puthli S.P., Eaimtrakarn S., Ishida M., Yoshikawa Y., Shibata N., and Takada K. Enhanced intestinal absorption of vancomycin with Labrasol and d-alpha-tocopheryl PEG 1000 succinate in rats. Int. J. Pharm. 250 1 (2003) 181-190
14. Constantinides P.P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 12 11 (1995) 1561-1572
15. Wang F., Wang C., Li M., Gui L., Zhang J., and Chang W. Purification, characterization and crystallization of a group of earthworm fibrinolytic enzymes from Eisenia fetida. Biotech. lett. 25 13 (2003) 1105-1109
16. Hou Q. A new medicine of state level "Lumbrokinase" and "Lumbrokinase Capsule" has been developed and prepared success. Prog. Biochem. Biophys. 21 1 (1994) 85
17. Park Y.D., Kim J.-W., Min B.-G., Seo J.-W., and Jeong J.-M. Rapid purification and biochemical characteristics of lumbrokinase III from earthworm for use as a fibrinolytic agent. Biotech. Lett. 20 (1998) 169-172
18. Fan Q., Wu C., Li L., Fan R., Wu C., Hou Q., and He R. Some features of intestinal absorption of intact fibrinolytic enzyme III-1 from Lumbricus rubellus. Biochim. Biophys. Acta 1526 3 (2001) 286-292
19. Li Y., Zhang M., Wang J., Zhang S., Liu J., and Zhang Q. Effects of absorption enhancers on intestinal absorption of lumbrokinase. Acta Pharm. Sin. 41 10 (2006) 939-944
20. Aboofazeli R., and Lawrence M.J. Investigations into the formation and characterization of phospholipid microemulsions. I. Pseudo-ternary phase diagrams of systems containing water-lecithin-alcohol-isopropyl myristate. Int. J. Pharm. 93 1-3 (1993) 161-175
21. Koga K., Kawashima S., and Murakami M. In vitro and in situ evidence for the contribution of Labrasol and Gelucire 44/14 on transport of cephalexin and cefoperazone by rat intestine. Eur. J. Pharm. Biopharm. 54 3 (2002) 311-318
22. Wu X.Q., Wu C., and He R.Q. Immobilized earthworm fibrinolytic enzyme III-1 with carbonyldiimidazole activated-agarose. Protein Pept. Lett. 9 1 (2002) 75-80
23. Toth O., Szabo C., Kecskes M., Poto L., Nagy A., and Losonczy H. In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters. Life Sci. 79 4 (2006) 317-323
24. Boudjeltia K.Z., Cauchie P., Remacle C., Guillaume M., Brohee D., Hubert J.L., and Vanhaeverbeek M. A new device for measurement of fibrin clot lysis: application to the euglobulin clot lysis time. BMC biotech. 2 (2002) 8
25. Lindmark T., Kimura Y., and Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. JPET 284 1 (1998) 362-369
26. Celebi N., Turkyilmaz A., Gonul B., and Ozogul C. Effects of epidermal growth factor microemulsion formulation on the healing of stress-induced gastric ulcers in rats. J. Control. Release 83 2 (2002) 197-210
27. Nakajima N., Mihara H., and Sumi H. Characterization of potent fibrinolytic enzymes in earthworm, Lumbricus rubellus. Biosci. Biotechnol. Biochem. 57 10 (1993) 1726-1730
28. Yamamoto A., Uchiyama T., Nishikawa R., Fujita T., and Muranishi S. Effectiveness and toxicity screening of various absorption enhancers in the rat small intestine: effects of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids from the intestinal membrane. J. Pharm. Pharmacol. 48 12 (1996) 1285-1289
29. Alany R.G., Rades T., Agatonovic-Kustrin S., Davies N.M., and Tucker I.G. Effects of alcohols and diols on the phase behaviour of quaternary systems. Int. J. Pharm. 196 2 (2000) 141-145
30. Podlogar F., Gasperlin M., Tomsic M., Jamnik A., and Rogac M.B. Structural characterisation of water-Tween 40/Imwitor 308-isopropyl myristate microemulsions using different experimental methods. Int. J. Pharm. 276 1-2 (2004) 115-128
31. Kreilgaard M., Pedersen E.J., and Jaroszewski J.W. NMR characterisation and transdermal drug delivery potential of microemulsion systems. J. Control. Release 69 3 (2000) 421-433
32. Beckwith-Hall B.M., Holmes E., Lindon J.C., Gounarides J., Vickers A., Shapiro M., and Nicholson J.K. NMR-based metabonomic studies on the biochemical effects of commonly used drug carrier vehicles in the rat. Chem. Res. Toxicol. 15 9 (2002) 1136-1141
33. Wolf G., and Kleinpeter E. Pulsed field gradient NMR study of anomalous diffusion in a lecithin-based microemulsion. Langmuir 21 15 (2005) 6742-6752
34. Libster D., Aserin A., and Garti N. A novel dispersion method comprising a nucleating agent solubilized in a microemulsion, in polymeric matrix II. Microemulsion characterization. J. Colloid Interface Sci. 302 1 (2006) 322-329
35. Garti N., Avrahami M., and Aserin A. Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution. J. Colloid Interface Sci. 299 1 (2006) 352-365
36. Bachmann L., and Talmon Y. Cryomicroscopy of liquid and semiliquid specimens: direct imaging versus replication. Ultramicroscopy 14 (1984) 211-218
37. Heizmann J., Langguth P., Biber A., Oschmann R., Merkle H.P., and Wolffram S. Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes. Peptides 17 7 (1996) 1083-1089
38. Langguth P., Bohner V., Heizmann J., Merkle H.P., Wolffram S., Amidon G.L., and Yamashita S. The challenge of proteolytic enzymes in intestinal peptide delivery. J. Control. Release 46 1-2 (1997) 39-57
39. Lyons K.C., Charman W.N., Miller R., and Porter C.J. Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion. Int. J. Pharm. 199 1 (2000) 17-28
40. Kompella U.B., and Lee V.H. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv. Drug Deliv. Rev. 46 1-3 (2001) 211-245
41. Sha X., Yan G., Wu Y., Li J., and Fang X. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur. J. Pharm. Sci 24 5 (2005) 477-486
42. Motlekar N.A., Srivenugopal K.S., Wachtel M.S., and Youan B.B. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J. Drug Target. 13 10 (2005) 573-583
43. Brayden D., Creed E., O'Connell A., Leipold H., Agarwal R., and Leone-Bay A. Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers. Pharm. Res. 14 12 (1997) 1772-1779
44. Aungst B.J. Intestinal permeation enhancers. J. Pharm. Sci. 89 4 (2000) 429-442
45. Geary R.S., and Wade Schlameus H. Vancomycin and insulin used as models for oral delivery of peptides. J. Control. Release 23 (1993) 65-74 (1)
46. Constantinides P.P., and Yiv S.H. Particle size determination of phase-inverted water-in-oil microemulsions under different dilution and storage conditions. Int. J. Pharm. 115 2 (1995) 225-234
47. Constantinides P.P., Welzel G., Ellens H., Smith P.L., Sturgis S., Yiv S.H., and Owen A.B. Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation. Pharm. Res. 13 2 (1996) 210-215